Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Seth

Showing results (361-370 of 415) with videos related to

Pageof 42
Sort By:
Journal of Medicinal Chemistry|January 30, 2010
Antisense oligonucleotides containing conformationally constrained 2',4'-(N-methoxy)aminomethylene and 2',4'-aminooxymethylene and 2'-O,4'-C-aminomethylene bridged nucleoside analogues show improved potency in animal modelsThazha P Prakash, Andrew Siwkowski, Charles R Allerson, et al.
Nucleic Acids Research|February 4, 2017
Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptorKarsten Schmidt, Thazha P Prakash, Aaron J Donner, et al.
Nucleic Acids Symposium Series (2004)|September 9, 2008
Design, synthesis and evaluation of constrained methoxyethyl (cMOE) and constrained ethyl (cEt) nucleoside analogsPunit P Seth, Andrew Siwkowski, Charles R Allerson, et al.
Bioorganic & Medicinal Chemistry Letters|June 9, 2016
Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytesGarth A Kinberger, Thazha P Prakash, Jinghua Yu, et al.
Journal of the American Chemical Society|September 17, 2011
Synthesis, improved antisense activity and structural rationale for the divergent RNA affinities of 3'-fluoro hexitol nucleic acid (FHNA and Ara-FHNA) modified oligonucleotidesMartin Egli, Pradeep S Pallan, Charles R Allerson, et al.
The Journal of Infectious Diseases|January 15, 2008
Ex vivo analysis of human T lymphotropic virus type 1-specific CD4+ cells by use of a major histocompatibility complex class II tetramer composed of a neurological disease-susceptibility allele and its immunodominant peptideHirohisa Nose, Ryuji Kubota, Nilufer P Seth, et al.
Cancer Gene Therapy|October 3, 2009
A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapyZ Hu, J S Robbins, A Pister, et al.
Nucleic Acids Research|May 5, 2017
Identification of metabolically stable 5΄-phosphate analogs that support single-stranded siRNA activityThazha P Prakash, Walt F Lima, Heather M Murray, et al.
Nucleic Acids Research|March 11, 2015
Identification of metabolically stable 5'-phosphate analogs that support single-stranded siRNA activityThazha P Prakash, Walt F Lima, Heather M Murray, et al.
Molecular Medicine (Cambridge, Mass.)|July 26, 2016
Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide ConjugateNoriko Satake, Connie Duong, Sakiko Yoshida, et al.
Pageof 42

Showing results (361-370 of 415) with videos related to

Sort By:
Pageof 42
Journal of Medicinal Chemistry|January 30, 2010
Antisense oligonucleotides containing conformationally constrained 2',4'-(N-methoxy)aminomethylene and 2',4'-aminooxymethylene and 2'-O,4'-C-aminomethylene bridged nucleoside analogues show improved potency in animal modelsThazha P Prakash, Andrew Siwkowski, Charles R Allerson, et al.
Nucleic Acids Research|February 4, 2017
Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptorKarsten Schmidt, Thazha P Prakash, Aaron J Donner, et al.
Nucleic Acids Symposium Series (2004)|September 9, 2008
Design, synthesis and evaluation of constrained methoxyethyl (cMOE) and constrained ethyl (cEt) nucleoside analogsPunit P Seth, Andrew Siwkowski, Charles R Allerson, et al.
Bioorganic & Medicinal Chemistry Letters|June 9, 2016
Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytesGarth A Kinberger, Thazha P Prakash, Jinghua Yu, et al.
Journal of the American Chemical Society|September 17, 2011
Synthesis, improved antisense activity and structural rationale for the divergent RNA affinities of 3'-fluoro hexitol nucleic acid (FHNA and Ara-FHNA) modified oligonucleotidesMartin Egli, Pradeep S Pallan, Charles R Allerson, et al.
The Journal of Infectious Diseases|January 15, 2008
Ex vivo analysis of human T lymphotropic virus type 1-specific CD4+ cells by use of a major histocompatibility complex class II tetramer composed of a neurological disease-susceptibility allele and its immunodominant peptideHirohisa Nose, Ryuji Kubota, Nilufer P Seth, et al.
Cancer Gene Therapy|October 3, 2009
A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapyZ Hu, J S Robbins, A Pister, et al.
Nucleic Acids Research|May 5, 2017
Identification of metabolically stable 5΄-phosphate analogs that support single-stranded siRNA activityThazha P Prakash, Walt F Lima, Heather M Murray, et al.
Nucleic Acids Research|March 11, 2015
Identification of metabolically stable 5'-phosphate analogs that support single-stranded siRNA activityThazha P Prakash, Walt F Lima, Heather M Murray, et al.
Molecular Medicine (Cambridge, Mass.)|July 26, 2016
Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide ConjugateNoriko Satake, Connie Duong, Sakiko Yoshida, et al.
Pageof 42